Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: Possibilities for therapeutic intervention

Nicole M. Davis, Melissa Sokolosky, Kristin Stadelman, Steve L. Abrams, Massimo Libra, Saverio Candido, Ferdinando Nicoletti, Jerry Polesel, Roberta Maestro, Antonio D'Assoro, Lyudmyla Drobot, Dariusz Rakus, Agnieszka Gizak, Piotr Laidler, Joanna Dulinska-Litewka, Joerg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Giuseppe Montalto, Melchiorre CervelloTimothy L. Fitzgerald, Zoya N. Demidenko, Alberto M. Martelli, Lucio Cocco, Linda S. Steelman, James A. McCubrey

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance and metastasis. The expression of this pathway is frequently altered in breast cancer due to mutations at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathway and upstream HER2 has been associated with breast cancer initiating cells (CICs) and in some cases resistance to treatment. The anti-diabetes drug metformin can suppress the growth of breast CICs and herceptin-resistant HER2+ cells. This review will discuss the importance of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but will also include relevant examples from other cancer types. The targeting of this pathway will be discussed as well as clinical trials with novel small molecule inhibitors. The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.

Original languageEnglish (US)
Pages (from-to)4603-4650
Number of pages48
JournalOncotarget
Volume5
Issue number13
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinases
Breast Neoplasms
Glycogen Synthase Kinase 3
Mutation
Therapeutics
Estrogen Receptor alpha
Metformin
mechanistic target of rapamycin complex 1
Tumor Suppressor Genes
Oncogenes
Drug Resistance
Clinical Trials
Hormones
Apoptosis
Neoplasm Metastasis
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • MTOR
  • Mutations
  • PI3K
  • Rapamycin
  • Targeted therapy
  • Therapy resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Davis, N. M., Sokolosky, M., Stadelman, K., Abrams, S. L., Libra, M., Candido, S., ... McCubrey, J. A. (2014). Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: Possibilities for therapeutic intervention. Oncotarget, 5(13), 4603-4650. https://doi.org/10.18632/oncotarget.2209

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer : Possibilities for therapeutic intervention. / Davis, Nicole M.; Sokolosky, Melissa; Stadelman, Kristin; Abrams, Steve L.; Libra, Massimo; Candido, Saverio; Nicoletti, Ferdinando; Polesel, Jerry; Maestro, Roberta; D'Assoro, Antonio; Drobot, Lyudmyla; Rakus, Dariusz; Gizak, Agnieszka; Laidler, Piotr; Dulinska-Litewka, Joanna; Basecke, Joerg; Mijatovic, Sanja; Maksimovic-Ivanic, Danijela; Montalto, Giuseppe; Cervello, Melchiorre; Fitzgerald, Timothy L.; Demidenko, Zoya N.; Martelli, Alberto M.; Cocco, Lucio; Steelman, Linda S.; McCubrey, James A.

In: Oncotarget, Vol. 5, No. 13, 01.01.2014, p. 4603-4650.

Research output: Contribution to journalArticle

Davis, NM, Sokolosky, M, Stadelman, K, Abrams, SL, Libra, M, Candido, S, Nicoletti, F, Polesel, J, Maestro, R, D'Assoro, A, Drobot, L, Rakus, D, Gizak, A, Laidler, P, Dulinska-Litewka, J, Basecke, J, Mijatovic, S, Maksimovic-Ivanic, D, Montalto, G, Cervello, M, Fitzgerald, TL, Demidenko, ZN, Martelli, AM, Cocco, L, Steelman, LS & McCubrey, JA 2014, 'Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: Possibilities for therapeutic intervention', Oncotarget, vol. 5, no. 13, pp. 4603-4650. https://doi.org/10.18632/oncotarget.2209
Davis, Nicole M. ; Sokolosky, Melissa ; Stadelman, Kristin ; Abrams, Steve L. ; Libra, Massimo ; Candido, Saverio ; Nicoletti, Ferdinando ; Polesel, Jerry ; Maestro, Roberta ; D'Assoro, Antonio ; Drobot, Lyudmyla ; Rakus, Dariusz ; Gizak, Agnieszka ; Laidler, Piotr ; Dulinska-Litewka, Joanna ; Basecke, Joerg ; Mijatovic, Sanja ; Maksimovic-Ivanic, Danijela ; Montalto, Giuseppe ; Cervello, Melchiorre ; Fitzgerald, Timothy L. ; Demidenko, Zoya N. ; Martelli, Alberto M. ; Cocco, Lucio ; Steelman, Linda S. ; McCubrey, James A. / Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer : Possibilities for therapeutic intervention. In: Oncotarget. 2014 ; Vol. 5, No. 13. pp. 4603-4650.
@article{da8f1565751a428bb82fb71745517ce7,
title = "Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: Possibilities for therapeutic intervention",
abstract = "The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance and metastasis. The expression of this pathway is frequently altered in breast cancer due to mutations at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathway and upstream HER2 has been associated with breast cancer initiating cells (CICs) and in some cases resistance to treatment. The anti-diabetes drug metformin can suppress the growth of breast CICs and herceptin-resistant HER2+ cells. This review will discuss the importance of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but will also include relevant examples from other cancer types. The targeting of this pathway will be discussed as well as clinical trials with novel small molecule inhibitors. The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.",
keywords = "MTOR, Mutations, PI3K, Rapamycin, Targeted therapy, Therapy resistance",
author = "Davis, {Nicole M.} and Melissa Sokolosky and Kristin Stadelman and Abrams, {Steve L.} and Massimo Libra and Saverio Candido and Ferdinando Nicoletti and Jerry Polesel and Roberta Maestro and Antonio D'Assoro and Lyudmyla Drobot and Dariusz Rakus and Agnieszka Gizak and Piotr Laidler and Joanna Dulinska-Litewka and Joerg Basecke and Sanja Mijatovic and Danijela Maksimovic-Ivanic and Giuseppe Montalto and Melchiorre Cervello and Fitzgerald, {Timothy L.} and Demidenko, {Zoya N.} and Martelli, {Alberto M.} and Lucio Cocco and Steelman, {Linda S.} and McCubrey, {James A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2209",
language = "English (US)",
volume = "5",
pages = "4603--4650",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "13",

}

TY - JOUR

T1 - Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer

T2 - Possibilities for therapeutic intervention

AU - Davis, Nicole M.

AU - Sokolosky, Melissa

AU - Stadelman, Kristin

AU - Abrams, Steve L.

AU - Libra, Massimo

AU - Candido, Saverio

AU - Nicoletti, Ferdinando

AU - Polesel, Jerry

AU - Maestro, Roberta

AU - D'Assoro, Antonio

AU - Drobot, Lyudmyla

AU - Rakus, Dariusz

AU - Gizak, Agnieszka

AU - Laidler, Piotr

AU - Dulinska-Litewka, Joanna

AU - Basecke, Joerg

AU - Mijatovic, Sanja

AU - Maksimovic-Ivanic, Danijela

AU - Montalto, Giuseppe

AU - Cervello, Melchiorre

AU - Fitzgerald, Timothy L.

AU - Demidenko, Zoya N.

AU - Martelli, Alberto M.

AU - Cocco, Lucio

AU - Steelman, Linda S.

AU - McCubrey, James A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance and metastasis. The expression of this pathway is frequently altered in breast cancer due to mutations at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathway and upstream HER2 has been associated with breast cancer initiating cells (CICs) and in some cases resistance to treatment. The anti-diabetes drug metformin can suppress the growth of breast CICs and herceptin-resistant HER2+ cells. This review will discuss the importance of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but will also include relevant examples from other cancer types. The targeting of this pathway will be discussed as well as clinical trials with novel small molecule inhibitors. The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.

AB - The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance and metastasis. The expression of this pathway is frequently altered in breast cancer due to mutations at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathway and upstream HER2 has been associated with breast cancer initiating cells (CICs) and in some cases resistance to treatment. The anti-diabetes drug metformin can suppress the growth of breast CICs and herceptin-resistant HER2+ cells. This review will discuss the importance of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but will also include relevant examples from other cancer types. The targeting of this pathway will be discussed as well as clinical trials with novel small molecule inhibitors. The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.

KW - MTOR

KW - Mutations

KW - PI3K

KW - Rapamycin

KW - Targeted therapy

KW - Therapy resistance

UR - http://www.scopus.com/inward/record.url?scp=84904968175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904968175&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2209

DO - 10.18632/oncotarget.2209

M3 - Article

C2 - 25051360

AN - SCOPUS:84904968175

VL - 5

SP - 4603

EP - 4650

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -